The total outcomes of both studies were reported in the Might issue of Neuropsychology, released by the American Psychological Association. The Centers for Disease Control in 2000 cited traumatic brain damage as the one most common reason behind death and disability in kids and adolescents. Long-Term Study Digs Out Individual Distinctions In the first research, researchers at The Ohio Condition University, Case Western Reserve University, and hospitals in Cleveland and Columbus followed 37 children after severe TBI, 40 children after moderate TBI, and 44 kids after musculoskeletal damage . All of the young children were injured between the age range of 6 and 12, and assessed six months, 12 months, and 3 to 5 years following their accidents.The researchers then found that lowering the known degree of cereblon allows the IMiDs to work properly. Interestingly, some resistant patients had normal cereblon levels, suggesting that while cereblon might be an absolute requirement of response, there are likely additional mechanisms present that play a role in drug resistance, stated senior study writer Keith Stewart, MD, Professor of Medicine in the Division of Hematology-Oncology and Dean of Analysis at Mayo Clinic in Scottsdale, Arizona. These findings help us understand which individuals could be more or less likely to react to therapy and invite us to spotlight other ways we are able to target cereblon just as one biomarker to boost treatment and individual outcomes in multiple myeloma.